Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02437916 · ClinicalTrials.gov registry record · Phase 1
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02437916 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 30 participants.
The verdict
NCT02437916, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
Interventions
- DRUG AMG 228
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-04-21 |
| Est. Completion | 2016-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02437916
The ClinicalTrials.gov registry entry for NCT02437916 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 228 is the first listed.
NCT02437916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02437916 about?
NCT02437916 is a clinical study titled "Safety Study of AMG 228 to Treat Solid Tumors". The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
What is the current status of trial NCT02437916?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-04-21. Estimated completion is 2016-12-12.
What interventions are being tested in trial NCT02437916?
The interventions under investigation include: AMG 228 (DRUG).
Who is sponsoring clinical trial NCT02437916?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.